Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × zipalertinib × 30 days × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Diseases 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 79 Carboplatin 65 Cisplatin 60 Paclitaxel 52 Specimen Handling 50 Magnetic Resonance Spectroscopy 48 Gemcitabine 46 Docetaxel 36 Cyclophosphamide 35 Pemetrexed 32 Dexamethasone 31 Doxorubicin 30 Fluorouracil 29 Bevacizumab 29 Radiotherapy 27 Capecitabine 27 durvalumab 26 Oxaliplatin 26 Rituximab 24 Radiation 24 Leucovorin 24 Vincristine 22 Lenalidomide 22 Nivolumab 18 Irinotecan 18 130-nm albumin-bound paclitaxel 18 venetoclax 17 Prednisone 17 Taxes 16 Letrozole 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973773 2026-03-10

REZILIENT3

Taiho Oncology, Inc.

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡